Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis
| Autor: | Maria Flavia Di Renzo, Nadia Coltella, Chiara Bardella, Peter Carmeliet, Martina Olivero, Cosimo Martino, Cristina Cammarata, Barbara Costa, Daniela Dettori, Annalisa Lorenzato |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Tumor suppressor gene
medicine.disease_cause Biochemistry Receptor tyrosine kinase Fumarate Hydratase Mice Neoplasms Genetics medicine Animals Molecular Biology Cells Cultured Gene knockdown biology Hepatocyte Growth Factor Tumor Suppressor Proteins Fibroblasts Proto-Oncogene Proteins c-met Hypoxia-Inducible Factor 1 alpha Subunit Cell Transformation Neoplastic Hypoxia-inducible factors Tumor progression Fumarase biology.protein Cancer research Hepatocyte growth factor Carcinogenesis Biotechnology medicine.drug |
| Popis: | Loss of the fumarate hydratase (FH) tumor suppressor gene results in the development of benign tumors that rarely, but regrettably, progress to very aggressive cancers. Using mouse embryo fibroblasts (MEFs) to model transformation, we found that fh knockdown results in increased expression of the met oncogene-encoded tyrosine kinase receptor through hypoxia-inducible factor (hif) stabilization. MET-increased expression was alone able to stabilize hif, thus establishing a feed forward loop that might enforce tumor progression. The fh-defective MEFs showed increased motility and protection from apoptosis. Motility, but not survival, relied on hif-1alpha and was greatly enhanced by MET ligand hepatocyte growth factor. Met cooperated with a weakly oncogenic ras in making MEFs transformed and tumorigenic, as shown by in vitro and in vivo assays. Loss of fh was not equally effective by itself but enhanced the transformed and tumorigenic phenotype induced by ras and MET. Consistently, the rescue of fumarase expression abrogated the motogenic and transformed phenotype of fh-defective MEFs. In conclusion, the data suggest that the progression of tumors where FH is lost might be boosted by activation of the MET oncogene, which is able to drive cell-autonomous tumor progression and is a strong candidate for targeted therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|